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Curcumin-loaded nanostructured lipid carrier induced 
apoptosis in human HepG2 cells through activation 
of the DR5/caspase-mediated extrinsic apoptosis pathway
Curcumin is a lipophilic anti-cancer compound extracted 
from turmeric. Our previous study demonstrated that the 
curcumin-loaded nanostructured lipid carrier (Cur-NLC) 
exhibits superior anti-cancer activity in inhibiting prolifera-
tion as well as inducing apoptosis of human HepG2 cells 
compared to native curcumin. This study aims to unveil the 
mechanisms underlying the pro-apoptotic effect of Cur-
NLC on HepG2 cells. Evidence indicates that low expression 
of death receptors (DRs) on cancer cell membranes leads to 
attenuated apoptosis signaling. This study showed that Cur-
NLC significantly increased total expression of DR5 protein 
while simultaneously upregulated cell membrane expres-
sion of DR5. Cur-NLC significantly increased caspase-8 and 
caspase-3 activities, accompanied by increased apoptosis. 
Furthermore, enhanced apoptosis was inhibited in the pres-
ence of a pan-caspase inhibitor, Z-VAD-FMK. Therefore, 
Cur-NLC induced activation of the extrinsic apoptosis path-
way via modulating the DR5/caspase-8/-3 mediated apopto-
sis pathway in HepG2 cells, suggesting that Cur-NLC is a 
promising therapeutic agent or supplement for the treatment 
of hepatocellular carcinoma.
Keywords: curcumin-loaded nanostructured lipid carrier, 
apoptosis, death receptor 5, caspase-8, caspase-3, HepG2 
cells
Surgical resection, liver transplant and chemotherapy currently act as main treatment 
options to control hepatocellular carcinoma (HCC), the prevailing primary malignancy of 
the liver (1). Nevertheless, the efficacy of several existing targeted therapies is often limited 
by the complicated pathogenesis of HCC and numerous unexpected effects of chemothera-
peutics, including drug resistance and unavoidable toxicity at effective doses (2). More-
over, unprecedented high cost also restricts clinical application of chemotherapeutic 
drugs. Thus, novel and effective alternative therapies with lower toxicity and improved 
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tracted growing attention as one of the best approaches for the discovery of new chemo-
therapeutic molecules due to their multi-target, multi-way, and low cytotoxicity profiles 
(3). To date, a large body of herbal medicine-derived compounds has been explored and 
reported to show anti-cancer activity and prevent the angiogenesis and metastasis of HCC 
(3). Therefore, curcumin, derived from the rhizome of Curcuma longa L. (commonly known 
as turmeric), was chosen for this investigation. It is a predominant constituent of cur-
cuminoids and has been used as a golden spice and coloring agent for a long time in food 
industry, or for centuries for its medicinal benefits mainly in Asian countries including 
India and China (4). Clinical studies have revealed that curcumin possesses anti-cancer 
activity by suppressing tumor initiation, promotion and metastasis alone or in combinati-
on with other anti-cancer drugs (5). The anti-cancer activity of curcumin is probably at-
tributed to its pleiotropic effects; it suppresses cancer cell proliferation and induces apop-
tosis in cancer cells (6). Notably, direct evidence from clinical trials indicates that 
curcumin works well and has excellent tolerability of high doses with very low toxicity, 
which is highly attractive and exciting for the therapeutic use of curcumin (7).
Despite its promise, curcumin as a lipophilic polyphenol has poor gastrointestinal 
absorbability and low systemic bioavailability in humans (8). Hence, the largest barrier for 
curcumin in cancer related therapy is to realize its full potential therapeutic efficacy. To 
circumvent these problems, the effectiveness of nanoparticulated curcumin has been tested 
against a number of cancer cell lines including HCC (9). Data showed nanoparticulated 
curcumin not only apparently improved the anti-cancer efficacy of curcumin but also in-
creased its bioavailability compared to an identical amount of native curcumin (9). We 
have recently developed a curcumin-loaded nanostructured lipid carrier (Cur-NLC) that 
not only considerably enhanced the systemic bioavailability of this agent but also im-
proved its anti-cancer activity in human lung A549 cells via enhancing cellular uptake and 
internalization of native curcumin (10). Previous data from our group revealed that Cur-
NLC apparently increased hepatocarcinoma cell death in a concentration-dependent man-
ner compared to native curcumin (11); however, the possible mechanisms underlying the 
induction of cell death have not been elucidated. It is therefore particularly interesting to 
understand the potential anti-cancer activity of Cur-NLC against human HepG2 hepato-
carcinoma cells.
Induction of cell death is the main approach to eradicating cancer cells from the body. 
One of the major forms of cell death is apoptosis, which can be a powerful tool in the che-
motherapy for cancer. Decrease of apoptosis is involved in both tumorigenesis and chemo-
resistance, which are the most common causes of treatment failures (12). A group of cyste-
ine proteases called caspases are triggered by either intrinsic (mitochondrion-mediated) 
or extrinsic [(death receptor (DR)-mediated] apoptosis pathways. Extrinsic apoptotic path-
way is initiated on the cell surface by ligation of a ligand to death receptors 4 (DR4) and 
DR5. Ligated DR promotes the formation of a death-inducing signaling complex (DISC) at 
the plasma membrane and subsequently transmits apoptosis signals via recruitment of 
adaptor molecules such as caspase-8 and caspase-10, leading to the activation of caspase-3 
and induction of cellular apoptosis (13). Both DR4 and DR5 contain a conserved cytoplas-
mic region that is referred to as ‘death domain’, which is required for tumor-necrosis- 
-factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Since DR4 and DR5-
induced apoptosis has been investigated against cancers, a better understanding of the role 
and mechanism/s of Cur-NLC mediated regulation of DR4 and DR5-induced apoptosis 
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may result in a novel therapeutic opportunity against HCC. To the best of our knowledge 
and belief, this is the first study demonstrating the role of DRs/caspases-mediated extrinsic 
apoptosis pathways involved in Cur-NLC induced HepG2 cell apoptosis.
EXPERIMENTAL
Materials
Curcumin (purity > 98 %) and Tween-80 were purchased from Sinopharm Chemical 
Reagent Co., Ltd. (China). Lecithin and octyl decyl acid triglycerate were provided by 
Anhui Fengyuan Pharmaceutical Co., Ltd. (China). Poloxamer 188 (Pluronic F68) was pur-
chased from BASF (Germany). Monostearin (MS) was obtained from Hunan Er-Kang 
Pharmaceutical Co., Ltd. (China). HPLC grade methanol was purchased from Merck (Ger-
many). RPMI-1640 medium, defined fetal bovine serum (FBS), dimethyl sulfoxide (DMSO) 
and 1 % penicillin-streptomycin were obtained from Gibco Co. (USA). DR4 (D-6, sc-166624), 
DR5 (B-9, sc-8411) and β-actin (C4, sc-47778) primary antibodies were obtained from Santa 
Cruz Biotechnology (USA). Secondary horseradish peroxide (HRP)-conjugated anti-mouse 
IgG antibody was obtained from Boster Bio-engineering Limited Company (China). RIPA 
lysis buffer and BCA protein assay kit were from Beyotime Biotechnology (China). An-
nexin V-ﬂuorescein isothiocyanate/propidium iodide (Annexin V-FITC/PI) was purchased 
from Nanjing Keygen Biotech Co., Ltd. (China). Caspase -8, -10, and -3 colorimetric Assay 
Kits (BB-4107-2/BB-4112-2/BB-4106-2) were obtained from Shanghai BestBio Co., Ltd. (China). 
Enhanced chemiluminescence (ECL) reagent was bought from Pierce (USA). Caspase 
 inhibitor Z-VAD-FMK (S7023) was purchased from Selleck.cn (China). Deionized water 
was provided by a Milli-Q Reference Ultrapure Water System, Merck (Germany). All other 
chemicals used in the experiment were of analytical grade.
Preparation of Cur-NLC
Curcumin-loaded solid lipid nanoparticles (Cur-SLN) were formulated as previously 
reported by our group (14). An NLC is a modified SLN with much more disordered and less 
crystalline lipid matrix, which can considerably improve the loading capacity and release 
properties, decrease drug leakage and increase chemical stability of incorporated drugs. 
Based on the formulation procedure of Cur-SLN, Cur-NLC was formulated by adding an 
additional liquid lipid (octyl decyl acid triglycerate). In brief, the lipid phase and the lipo-
philic surfactant were dissolved in moderate amounts of organic solvents and a homoge-
neous solution was obtained when heated up to 75 °C. After adding curcumin, the lipid 
phase was poured into the aqueous solution of hydrophilic surfactant and heated up to 75 °C, 
accompanied by high speed stirring (1000 rpm) for 2 h to form a pre-emulsion. The resulting 
hot o/w nano-emulsion was dispersed into ice-cold distilled water immediately under gentle 
mechanical stirring for 2 h. Cur-NLC was formed by lipid recrystallization. Orthogonal tests 
were conducted to optimize the composition of the solid lipid, liquid lipid and the surfac-
tants. Using photon correlation spectroscopy with Zetasizer (Nano ZS90, Malvern, UK), the 
physicochemical characteristics including mean particle size, polydispersity index (PDI) and 
Zeta potential were determined after appropriate dilution with deionized water. The encap-
su lation efficiency (EE) and drug loading (DL) of Cur-NLC were assessed indirectly by 
HPLC analysis based on the following equation:
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EE % = (mtotal – mfree)/mtotal × 100 %
and
DL % = (mtotal – mfree)/(mtotal + mLipid) × 100 %,
where mtotal, mfree were the weight of total drug in the system and weight of free drug in the 
filtrate, respectively; and mLipid was the weight of lipid material. The mean particle diameter, 
zeta potential, PDI, EE and DL of Cur-NLC were 99.99 ± 1.87 nm, −19.9 ± 0.65 mV, 0.158 ± 0.005, 
(97.86 ± 0.72) %, and (4.35 ± 0.12) %, respectively. Empty NLC were prepared by the same 
procedure without adding curcumin.
Human HepG2 cell culture
Human HepG2 cell line was obtained from the Shanghai Cell Bank, Chinese Academy 
of Sciences (China). HepG2 cell was incubated in the RPMI-1640 medium with 10 % fetal 
bovine serum containing 100 U mL–1 penicillin and 100 μg mL–1 streptomycin at 37 °C and 
5 % CO2. Cells in the exponential growth phase were used for experiments. Cur-NLC and 
empty NLC were prepared as 80 mg L–1 stock solutions stored at –20 °C and diluted to dif-
ferent working solutions with medium before the treatment. After 24 h, the cells were 
collected and stored at –20 °C for different analyses as described below.
Determination of DR4 and DR5 proteins by Western blot analysis
Cells were collected, washed with ice-cold PBS and lysed at a density of 0.5 × 106 cells 
mL–1 of RIPA lysis buffer containing 10 mM phenylmethylsulfonyl ﬂuoride (PMSF) and 0.1 
% sodium dodecyl sulfate (SDS) for 30 min on ice. The BCA protein assay was used for 
measuring protein concentration according to the recommended guidelines. One protein 
sample was mixed with 5× sample buffer (4:1) and denatured at 95 °C for 10 min. The pro-
teins were resolved by SDS-PAGE and then transferred onto a polyvinylidene diﬂuoride 
membrane (Millipore, Bedford, MA) in transfer buffer (25 mM Tris-base, 192 mM glycine, 
and 20 % methanol) at 4 °C for 2 h. After blocking with 5 % non-fat dry milk dissolved in 
0.05 % Tween 20-PBS, the membranes were incubated with the primary mouse anti-DR4 
and anti-DR5 antibody under gentle agitation at 4 °C for 24 h. After washing 3 times with 
PBS, the membranes were probed with an HRP-conjugated anti-mouse IgG antibody. Im-
munodetection was performed using ECL reagent according to the manufacturer’s proto-
cols. Equivalent protein loading and transfer efficiency were checked by staining for 
β-actin (a housekeeping gene). Control groups included cells treated only with complete 
growth culture medium (control) and cells treated with empty NLC (NLC control). All the 
experiments were performed in triplicate. The relative intensity of protein expression was 
normalized to β-actin. Autoradiographs were scanned using an Alpha Chemiluminescent 
gel imaging system FluorChem FC3 (ProteinSimple, Silicon Valley, USA) and quantified 
using ImageJ software (version 1.45S, NIH, USA).
Determination of cell membrane proteins DR4 and DR5 by flow cytometry analysis
Surface expression of membrane proteins DR4 and DR5 was quantified using the im-
munoﬂuorescence labeling assay. Cells (2 × 106 cells mL–1) were washed twice with cold 
PBS and fixed with 4 % paraformaldehyde at room temperature for 40 min. After centrifu-
gation at 1000 rpm for 5 min, the supernatant was discarded and cells were re-suspended 
in PBS, centrifuged at 1000 rpm for 5 min, and permeabilized with 0.1 % Triton X-100 in 
PBS. Samples were blocked with 0.5 % normal bovine serum albumin for 30 min and in-
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cubated with the primary antibodies at 4 °C overnight. After washing 3 times, cells were 
probed with a secondary ﬂuorescein isothiocyanate (FITC)-conjugated antimouse IgG an-
tibody and kept in a dark place for 1 h at 4 °C. After staining, cells were washed again with 
ice-cold PBS and re-suspended in PBS. 200 μL cell samples were transferred to 5 mL Falcon 
tubes and the samples were analyzed using a Flow Cytometer (USA). NLC control, model 
control (without primary antibody and secondary FITC-conjugated anti-mouse IgG anti-
body) and isotype (without primary antibody) groups were used as controls. Experiments 
were performed in triplicate; data compensation and the mean ﬂuorescence intensity from 
different samples were performed using the FlowJo Version 7.6.1 software (USA).
Apoptosis analysis by flow cytometry
To confirm whether caspases participate in Cur-NLC induced HepG2 cell apoptosis, 
the effect of Cur-NLC combined with caspase inhibitor (Z-VAD-FMK) on the HepG2 cell 
apoptosis rate was analyzed by ﬂow cytometry. HepG2 cells were stained with an Annexin 
V-FITC/PI apoptosis detection kit that detects phosphatidylserine exposed to the outer 
surface of the cell membrane for ﬂuorescence-activated cell sorting (FACS) analysis. In 
brief, HepG2 cells (0.5 × 106 cells per well) were added into a 6-well plate and cultured 
until 75~85 % conﬂuence. Cells were then treated with Cur-NLC (10 μmol L–1) and Cur-
NLC (10 μmol L–1) combined with Z-VAD-FMK (20 μmol L–1), respectively. The model 
group (cells cultured with complete growth culture medium only) and the NLC control 
group acted as controls. After 48 h, cells were collected by trypsinization and washed 3 
times with cold PBS and centrifuged at 1000 rpm for 5 min. Cells were stained by adding 
Annexin V-FITC/PI into binding buffer. Stained cells were put in a dark place at 37 °C for 
15 min. Processed single cell suspensions were analyzed with a ﬂow cytometer. Triplicate 
of each sample was examined and data compensation was performed using FlowJo Ver-
sion 7.6.1 software. It should be noted that cells staining negative for both annexin V and 
PI are live cells, cells labelled with annexin V+/PI− are in early apoptosis phase, and cells 
labelled with annexin V+/PI+ are in the necrotic or late apoptosis phase.
Measurement of Caspase-8, -10, -3 activation
To measure caspase activity, caspase-8, -10, and -3, colorimetric assay kits were used 
according to the manufacturer’s instructions. The assay was based on the spectrophoto-
metric detection of chromophore p-nitroanilide (pNA) after cleavage from the labeled sub-
strate DEVD-pNA. The cells (1 × 106) were harvested, lysed and incubated on ice for 30 min. 
Protein lysate was collected and quantified. Protein samples (100 μg) were placed into a 
96-well plate and mixed respectively with 4 mmol L–1 DEVD-pNA (caspase-3), IETD-pNA 
(caspase-8) and AEVD-pNA (caspase-10). The mixtures were then incubated at 37 °C for 2 h 
in the dark and then the activity was measured at 405 nm using a microplate reader (BioTek 
Elx × 800 microplate reader, Winooski, VT, USA). The experiment was performed in triplicate. 
Comparison of the absorbance of p-NA from an apoptotic sample with an uninduced control 
allows determination of the fold increase in caspase activity.
Statistical analysis
Each experiment was conducted in triplicate and the values were expressed as mean 
± standard deviations (SD). Biostatistical analyses were assessed using GraphPad Prism 
version 5.0 for Windows (GraphPad software, San Diego California USA, www.graphpad.
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com). Statistical comparisons of multiple groups were performed with one-way ANOVA 
followed by the Student-Newman-Keuls post hoc test and p < 0.05 was considered as stati-
stically significant.
RESULTS AND DISCUSSION
Cur-NLC increased the expression of DR5 protein in HepG2 cells
DR4 and DR5, as death receptors on the surface of cells, can promote one of the apop-
totic pathways, that is, the extrinsic pathway, through DISC assembly and subsequent ac-
tivation of caspases. Therefore, any change concerning the protein expression level of the 
two death receptors exerts a profound inﬂuence on apoptosis signaling. Hence, aberrant 
cell surface expression of DR4 and DR5 might play a critical role in the death-inducing 
ability. In this regard, surface expression of DR4 and DR5 could be evaluated as a predic-
tive biomarker for identifying patient subpopulations with tumors that are responsive or 
resistant to death receptor targeted agents.
It is worth noting that DR5 may make a greater contribution than DR4 to TRAIL-in-
duced apoptosis in cancer cells (which express both death receptors). The present study 
Fig. 1. Effect of Cur-NLC on the total protein expression of death receptor 5 (DR5) in human HepG2 
cells (x ± s, n = 3): a) Total protein expression of DR5 in HepG2 cells assessed by Western blot analysis; 
b) Bar graphs represent quantitative evaluation of DR5 bands by densitometry from triplicate inde-
pendent experiments. Representative image of the immunoblot for DR5 is shown. Relative protein 
level of DR5 was analyzed using β-Actin as a loading control. *p < 0.05, **p < 0.01 compared to the 
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measured the total and cell surface protein expression of DR4 and DR5 after Cur-NLC 
treatment. To investigate whether Cur-NLC has anti-cancer ability against HepG2 cells, we 
treated HepG2 cells with Cur-NLC at doses of 5, 10 and 20 μmol L–1 for 48 h based on our 
previous results (11). As shown in Fig. 1, HepG2 cells treated with Cur-NLC resulted in 
upregulation of total DR5 protein expression compared to control cells. It seems that the 
expression of DR5 in NLC groups was higher than that of the control group, but it did not 
reach a significant difference. Furthermore, to determine whether Cur-NLC increased the 
protein expression of DR5 on cell surface, the cells were subjected to an immunoﬂuores-
cence labeling assay. Flow cytometry analysis showed that the protein expression of cell 
membrane DR5 increased in a concentration-dependent manner after treatment with Cur-
NLC compared to the control group (Fig. 2), which is consistent with the result of Western 
blot. No significant changes in total and membrane DR4 protein expression were observed 
Fig. 2. Effect of Cur-NLC on the translocation of death receptor 5 (DR5) to the plasma membrane 
surface (x ± s, n = 6): a) Membrane protein expression of DR5 in HepG2 cells examined by ﬂow cyto-
metric analysis; b) Bar graphs show quantitative evaluation of DR5 bands from triplicate independent 
experiments by the biological image analysis system. Model group represents cells cultured with 
complete growth culture medium only, and NLC group represents cells treated with NLC without 
curcumin in the same concentration as Cur-NLC group (10 μmol L–1).
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after treatment with Cur-NLC (Supplementary Fig. S1 and S2). The data indicated that Cur-
NLC increased the expression of DR5, but not DR4 in human HepG2 cells (Fig. 1). Hence, 
therapeutic drugs that can upregulate DR5 protein expression may be likely to increase 
cellular sensitivity to apoptosis therapies.
Caspases activation is involved in Cur-NLC induced apoptosis
Similar results for protein expression of total DR5 and membrane DR5 indicate that 
Cur-NLC could significantly induce enhanced DR5 expression in HepG2 cells. In general, 
DR5-dependent apoptosis involves a cascade of events, such as activation of caspases, 
which is commonly considered to have a predominant role in apoptosis signaling path-
ways. To further evaluate the involvement of the extrinsic pathway apoptosis of HepG2 
cells induced by Cur-NLC, the effects of Cur-NLC combined with the pan-caspase inhibitor 
(Z-VAD-FMK) on the HepG2 cell apoptosis rate were assessed. HepG2 cells were pre-
treated with Z-VAD-FMK for 2 h before Cur-NLC treatment. Flow cytometry was used to 
detect the apoptosis rate of treated cells. As shown in Fig. 3, an apparent increase in the 
percentage of HepG2 cell apoptosis was observed immediately after Cur-NLC (10 μmol 
L–1) treatment compared to the control. However, a significant decrease of Cur-NLC in-
duced apoptosis was found in the presence of Z-VAD-FMK (20 μmol L–1) compared to the 
Fig. 3. Effects of Cur-NLC and the pan-caspase inhibitor (Z-VAD-FMK) on HepG2 cell apoptosis rate 
(x ± s, n = 3): a) Apoptotic cells detected by ﬂow cytometry. Cells were treated with Cur-NLC (10 μmol L–1) 
and pre-treated with Z-VAD-FMK at 20 μmol L–1 for 2 h before Cur-NLC treatment. Model group 
represents cells cultured with complete growth culture medium only, and NLC group represents 
cells treated with NLC without curcumin in the same concentration as Cur-NLC group (10 μmol L–1). 
The lower right quadrant (annexin V+/PI−) represents early apoptosis, while the upper right quadrant 
(annexin V+/PI+) represents late apoptosis or necrosis; b) Bar graphs represent the apoptosis rate of 
each group analyzed from triplicate independent experiments by GraphPad prism 5 software. # p < 0.05, 
## p < 0.01 vs. model control group; **p < 0.01 vs. Cur-NLC group.
a)
                                                                                                    b)
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cells treated with Cur-NLC alone. These results indicate that caspase activation is clearly 
associated with Cur-NLC induced apoptosis.
Effect of Cur-NLC on caspase-8, -10 and -3 activity
Within the extrinsic apoptotic pathway, caspase-8 is the most proximal caspase that 
transmits apoptotic signals originating at the membrane of DRs (15). In order to investigate 
the possible mechanism underlying caspases-mediated apoptotic events, the effects of co-
administration of Cur-NLC with caspase inhibitor on the activation of caspase-8, -10 and 
-3 were evaluated. Following Cur-NLC treatment, the activity of caspase-8 and -3 were 
remarkably increased in HepG2 cells compared to the control. However, co-treatment of 
Cur-NLC with Z-VAD-FMK strongly suppressed the activity of caspase-8 and -3 (Fig. 4A 
and B). No significant change was found in the activity of caspase-10 after treatment with 
Cur-NLC (Supplementary Fig. S3).
Taken together, these data suggest that Cur-NLC-induced HepG2 cell apoptosis may 
be mediated via an extrinsic death receptor pathway mechanism, i.e., through DR5 up-
regulation and activation of caspase-8 and caspase-3.
CONCLUSIONS
Curcumin widespread availability, superior safety profile, low cost and multiple can-
cer fighting functions make it a potent anti-cancer herbal extract. The novelty of this study 
lies in the finding that Cur-NLC modulated DR5/caspase-8/-3 mediated extrinsic apoptosis 
Fig. 4. Effects of Cur-NLC on caspase-8 and caspase-3 activities in HepG2 cells: a) Caspase-8 activa-
tion was determined by spectrophotometric detection of their cleavages by caspase-8 colorimetric 
assay kits (x ± s, n = 3); b) Caspase-3 activation was determined by spectrophotometric detection of 
their cleavages by caspase-3 colorimetric assay kits. Model group represents cells cultured with com-
plete growth culture medium only, and NLC group represents cells treated with NLC without cur-
cumin in the same concentration as Cur-NLC group (20 μmol L–1). *p < 0.05, **p < 0.01 vs model control 
group; #p < 0.05, ##p < 0.01 vs. Cur-NLC group.
a)                                                                             b)
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pathway involved in HepG2 cell apoptosis. Thus, our previous and present studies col-
lectively suggest that Cur-NLC may be a potential therapeutic and preventative drug for 
HCC in increasing cellular sensitivity to apoptosis. However, more preclinical as well as 
clinical studies are necessary to unveil the mechanisms underlying the pro-apoptotic ef-
fect of Cur-NLC on HCC. For instance, it is necessary to elucidate how, by targeting ap-
propriate signal transducers, the Cur-NLC mediated apoptotic pathway works in the dif-
ferent HCC cell lines and animal models. More exact experiments will be carried out to 
unveil detailed pro-apoptotic effects of Cur-NLC in the extrinsic death receptor pathway. 
The proposed in vivo and in vitro studies for the molecular basis would provide valuable 
insights to evaluate the applicability of curcumin as a chemopreventive and/or therapeutic 
agent for HCC.
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